09:00am Chair Introduction

Lynn Fisher, Chief Executive Officer, Title 21 Software

09:05am Presentation: Implementing Cell Orchestration Systems Within an Established Clinical Trial Management Digital Ecosystem

• Autologous cell therapies require interaction of the clinical and supply chain/manufacturing systems to enable supply management and COI/COC
• Building a platform around the patient journey is key to success

Lydia Jordan, Principal Investigator, Clinical CGT Supply Chain Lead, GlaxoSmithKline

09:20am Presentation: Addressing Industry Challenges in Cell and Gene Therapy Supply Chain Through Integrated End-to-End Solutions

• Lessons learned/best practices to mitigate risk in your supply chain and to accelerate path to commercialization
• How to address unique challenges for CGT supply chain through use of integrated systems/solutions

Andreas Kouri, Senior Vice President, Supply Chain Strategic Operations, ElevateBio

09:35am Presentation: A Standardized Format for the Chain of Identity (CoI) Identifier

• Collaborative process to develop a standardized CoI Identifier
• CoI Identifier data structure
• How to become an issuer for the ISBT 128 CoI Identifier

 Karen Moniz, Technical Director, ICCBBA

09:50am Presentation: Addressing Logistical Challenges – How Albumin Can Improve Storage and Stability of Cells

• • Protect against loss of live cells numbers and cell viability post-thaw with reduced DSMO conc.
  • Increase hold time and reduce the number of apoptotic cells post thaw.
  • Your choice of albumin matters; different albumin sources and formulations

Phil Morton, Chief Technology Officer, Albumedix

10:05am Closing Panel with Q&A

With all session participants